Valproate (Depakote): Uses, Dosage, Side Effects, and What to Expect

Valproic acid / divalproex sodium (brand name: Depakote, Depakene, Depacon) is a mood stabilizer / anticonvulsant (branched-chain fatty acid). Valproate has multiple mechanisms: it increases brain GABA levels (by inhibiting GABA transaminase and enhancing GABA synthesis), blocks voltage-gated sodium channels (anticonvulsant effect), modulates intracellular signaling cascades (including GSK-3 and ERK pathways), and has histone deacetylase (HDAC) inhibitor activity (epigenetic effects). This broad mechanism explains its efficacy across multiple conditions — epilepsy, bipolar mania, and migraine — but also its broad side effect profile.

• Epilepsy (multiple seizure types)
• Bipolar I Disorder (acute manic episodes — Depakote)
• Migraine prophylaxis (Depakote ER)

Common off-label uses:

• Bipolar maintenance
• Bipolar depression (limited evidence)
• Schizoaffective disorder
• Impulse control disorders
• Agitation in dementia
• Neuropathic pain

Bipolar mania: start 250 mg three times daily or loading dose 20-30 mg/kg/day; target serum level 50-125 mcg/mL. Depakote ER: start 25 mg/kg/day once daily. Epilepsy: 10-60 mg/kg/day. Migraine: 500-1000 mg/day. Monitor serum levels — therapeutic range varies by indication.

Antimanic effects may begin within days with loading dose strategy. Full mood stabilization: 1-2 weeks. Migraine prophylaxis: 4-8 weeks.

• Nausea and GI upset (reduced with Depakote/divalproex formulation)
• Weight gain (significant — average 5-10 kg)
• Tremor
• Hair loss/thinning
• Sedation
• Dizziness
• Elevated liver enzymes (usually transient)

• Hepatotoxicity (potentially fatal — highest risk in children <2 years on polytherapy; monitor LFTs)
• Pancreatitis (potentially fatal — discontinue if suspected)
• Teratogenicity (neural tube defects in 1-2% of exposed pregnancies; reduced IQ in children — STRONGEST teratogen among mood stabilizers)
• Thrombocytopenia (dose-dependent)
• Hyperammonemic encephalopathy (can occur with normal liver function)
• Polycystic ovarian syndrome (with chronic use in women)
• Bone loss with long-term use

Highly protein-bound — displaces and is displaced by other protein-bound drugs. Doubles lamotrigine levels (critical interaction — lamotrigine dose must be halved). Aspirin increases free valproate levels. Carbapenems (meropenem, ertapenem) drastically reduce valproate levels (avoid combination). CYP2C9 inhibitor — increases levels of phenobarbital and warfarin.

CONTRAINDICATED in pregnancy when used for bipolar disorder or migraine. FDA Category D (Category X for migraine). The most teratogenic mood stabilizer: 1-2% risk of neural tube defects (spina bifida), 10-15% risk of major malformations overall, dose-dependent IQ reduction (average 8-9 points below controls), and increased risk of autism spectrum disorder. All women of childbearing potential must use effective contraception. If pregnancy occurs, switch to a safer alternative immediately.

Taper gradually over 1-2 weeks to reduce seizure risk (even in non-epileptic patients). Rebound mania possible with abrupt discontinuation.